EHA 2026 | Outcomes and risk factors in children and young adults with ALL and high-risk genetics
Anthony Moorman, PhD, Newcastle University, Newcastle, UK, provides insight into a study of outcomes and risk factors in children and young adults with acute lymphoblastic leukemia (ALL) and high-risk genetics, highlighting that patients with near-haploidy or low-hypodiploidy continue to have the poorest outcomes despite intensive chemotherapy. Prof. Moorman notes that this subgroup also appears to be resistant to both chemotherapy and immunotherapy, which is a major concern, as they may not respond to novel therapies such as blinatumomab. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
